Study Identifies Key Mutations That Make New DNA Repair Enzyme Inhibitors More Effective
PHILADELPHIA (November 28, 2023) — Research into alternative therapies for breast and ovarian cancers that contain BRCA1, PALB2, or BRCA2 mutations has focused on developing new drugs targeting an enzyme that helps repair damaged DNA. But a study published in the prestigious journal Nature Communications by researchers at Fox Chase Cancer Center shows that this approach may be most effective for PALB2 and BRCA2 mutation-containing cancers.